Untargeted metabolomics analysis reveals spatial metabolic heterogeneity in different intestinal segments of type 1 diabetic mice†

IF 3 4区生物学 Q3 BIOCHEMISTRY & MOLECULAR BIOLOGY

Molecular omics Pub Date : 2023-11-07 DOI:10.1039/D3MO00163F

Kaiyan Gong, Junli Chen, Xiaoli Yin, Mengjun Wu, Hong Zheng and Lingling Jiang

引用次数: 0

Abstract

Type 1 diabetes (T1D) has been reported to cause systematic metabolic disorders, but metabolic changes in different intestinal segments of T1D remain unclear. In this study, we analyzed metabolic profiles in the jejunum, ileum, cecum and colon of streptozocin-induced T1D and age-matched control (CON) mice by an LC-MS-based metabolomics method. The results show that segment-specific metabolic disorders occurred in the gut of T1D mice. In the jejunum, we found that T1D mainly led to disordered amino acid metabolism and most amino acids were significantly lower relative to CON mice. Moreover, fatty acid metabolism was disrupted mainly in the ileum, cecum and colon of T1D mice, such as arachidonic acid, alpha-linolenic acid and linoleic acid metabolism. Thus, our study reveals spatial metabolic heterogeneity in the gut of T1D mice and provides a metabolic view on diabetes-associated intestinal diseases.

Abstract Image

查看原文本刊更多论文

非靶向代谢组学分析揭示了 1 型糖尿病小鼠不同肠段的空间代谢异质性†。

据报道，1 型糖尿病（T1D）会引起系统性代谢紊乱，但 T1D 不同肠段的代谢变化仍不清楚。在这项研究中，我们采用基于 LC-MS 的代谢组学方法分析了链脲佐菌素诱导的 T1D 小鼠和年龄匹配的对照组（CON）小鼠空肠、回肠、盲肠和结肠的代谢谱。结果表明，T1D 小鼠的肠道出现了特定区段的代谢紊乱。在空肠中，我们发现 T1D 主要导致氨基酸代谢紊乱，与对照组小鼠相比，大多数氨基酸含量显著降低。此外，脂肪酸代谢紊乱主要发生在 T1D 小鼠的回肠、盲肠和结肠，如花生四烯酸、α-亚麻酸和亚油酸代谢紊乱。因此，我们的研究揭示了 T1D 小鼠肠道代谢的空间异质性，并为糖尿病相关肠道疾病提供了一个代谢视角。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Molecular omics Biochemistry, Genetics and Molecular Biology-Biochemistry

CiteScore

5.40

自引率

3.40%

发文量

期刊介绍： Molecular Omics publishes high-quality research from across the -omics sciences. Topics include, but are not limited to: -omics studies to gain mechanistic insight into biological processes – for example, determining the mode of action of a drug or the basis of a particular phenotype, such as drought tolerance -omics studies for clinical applications with validation, such as finding biomarkers for diagnostics or potential new drug targets -omics studies looking at the sub-cellular make-up of cells – for example, the subcellular localisation of certain proteins or post-translational modifications or new imaging techniques -studies presenting new methods and tools to support omics studies, including new spectroscopic/chromatographic techniques, chip-based/array technologies and new classification/data analysis techniques. New methods should be proven and demonstrate an advance in the field. Molecular Omics only accepts articles of high importance and interest that provide significant new insight into important chemical or biological problems. This could be fundamental research that significantly increases understanding or research that demonstrates clear functional benefits. Papers reporting new results that could be routinely predicted, do not show a significant improvement over known research, or are of interest only to the specialist in the area are not suitable for publication in Molecular Omics.